Lv21
170 积分 2022-06-06 加入
Research progress in OX40/OX40L in allergic diseases
20天前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
27天前
已关闭
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
27天前
已关闭
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
27天前
已完结
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
1个月前
已完结
Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling
1个月前
已完结
Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes
1个月前
已完结
A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts
2个月前
已完结
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody
2个月前
已完结
Interleukin-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma
2个月前
已关闭
皖公网安备34019202002308
